• Like
  • Comment
  • Favorite

Oncocyte To Announce Third Quarter 2024 Financial Results on Nov. 12

GlobeNewswire2024-11-06

Conference Call and Webcast on Tuesday, November 12, 2024, at 2:00 p.m. PT / 5:00 p.m. ET

IRVINE, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp. (Nasdaq: OCX), a diagnostics technology company, announced today that the company will release its third quarter 2024 financial results on Tuesday, November 12, 2024, after U.S. market closes. The company will also host a conference call and webcast on Tuesday, November 12, 2024, at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and highlights.

Interested parties may access the live call via telephone by dialing toll free 800-715-9871 for domestic callers. Once dialed in, ask to be joined to the Oncocyte Corporation call.

The live webcast of the call may be accessed by visiting the “Events & Presentations” section of the Company’s website at https://investors.oncocyte.com. A replay of the webcast will be available on the Company’s website shortly after the conclusion of the call. 

CONFERENCE CALL DETAILS:
Participant Toll-Free Dial-In Number: (800) 715-9871
Participant Toll Dial-In Number: +1 (646) 307-1963
Conference ID: 4153469


WEBCAST DETAILS: https://events.q4inc.com/attendee/686764682

About Oncocyte
Oncocyte is a diagnostics technology company. The Company’s tests are designed to help provide clarity and confidence to physicians and their patients. VitaGraft™ is a clinical blood-based solid organ transplantation monitoring test. GraftAssure™ is a research use only (RUO) blood-based solid organ transplantation monitoring test. DetermaIO™ is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. DetermaCNI™ is a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients. For more information about Oncocyte, please visit https://oncocyte.com/.

For more information about our products, please visit the following web pages:

VitaGraft Kidney™ - https://oncocyte.com/vitagraft-kidney/
VitaGraft Liver™ - https://oncocyte.com/vitagraft-liver/
GraftAssure™ - https://oncocyte.com/graftassure/
DetermaIO™ - https://oncocyte.com/determa-io/
DetermaCNI™ - https://oncocyte.com/determa-cni/

VitaGraft™, GraftAssure™, DetermaIO™, and DetermaCNI™ are trademarks of Oncocyte Corporation.

CONTACT:
Jeff Ramson
PCG Advisory
(646) 863-6893
jramson@pcgadvisory.com




Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

empty
No comments yet
errorbox banner

抱歉,当前请求异常(-1)

7x24

  • 23:53

    Grand Banks Yachts Ltd - Stuart Yacht Corp to Acquire Two Properties in Newport for $21 Mln

  • 23:49

    Frasers Property Ltd - Acquisition Price for Proposed Transaction Approximately S$187.6 Million

  • 23:49

    Frasers Property Ltd - Enters Agreement to Sell 50% of Ng Trust Units

  • 23:45

    Sunac Services - Proposed to Declare a Final Dividend of RMB14.3 Cents per Share

  • 23:45

    Sunac Services Holdings FY Gross Margin 21.9%

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email:uservice@ttm.financial